Clinical trials

Terra Sigillata

Category archives for Clinical trials

Clever clinical trials redirect

When readers are looking for clinical trials information, particularly for cancer therapies, I often refer to the NIH-operated clinicaltrials.gov: ClinicalTrials.gov provides regularly updated information about federally and privately supported clinical research in human volunteers. ClinicalTrials.gov gives you information about a trial’s purpose, who may participate, locations, and phone numbers for more details. The information provided…

As I noted in a previous post on arsenic trioxide, you just never know what source will give rise to the next promising drug. Last week’s New England Journal of Medicine marked a key study on an old drug, mitotane (Lysodren, Bristol-Myers Squibb), that is a structural derivative of the pesticide, DDT. Adrenocortical carcinoma is…

Yesterday morning’s press release from the American Society for Clinical Oncology (ASCO) meeting included discussion of three abstracts on complementary therapies being tested in cancer and cancer-related indications. The highlights on the major news services are that 1) a shark cartilage extract failed to provide survival benefit in patients with non-small cell lung cancer, 2)…

Via my colleague, PharmCanuck, comes news of an in-depth radio program on dichloroacetate (DCA) that aired this past Tuesday on CBC’s, “The Current.” As a reminder to readers who aren’t already bored senseless of my discussion of this chemical, DCA is a small molecule freely-available in the public domain that was shown to slow the…

Today’s edition of the NCI Cancer Bulletin features another natural product clinical trial, this time for depsipeptide in T-cell lymphoma. Depsipeptide (Romidepsin or FR901228) is an early histone deacetylase inhibitor isolated from fermentation of Chromobacterium violaceum. Several histone deacetylase inhibitors are in clinical trials for various cancers and many are derived from natural products. However,…

Well, this sure doesn’t help

A bad day for pharma on the newswires: Pfizer subsidiaries agree to pay $34.7 million in fines Two subsidiaries of Pfizer Inc. have agreed to pay fines totaling $34.7 million for offering a kickback to recommend company drugs and for illegally promoting the human growth hormone product Genotropin for non-approved uses, federal prosecutors announced Monday.…

I noted just last week the latest review by Drs Newman and Cragg citing that nature remains the source of 70% of prescription drugs. Wall Street Journal medical reporter Ron Winslow took his turn yesterday contributing to the paper’s new HealthBlog from New Orleans, site of the American College of Cardiology meeting. Turns out that…